Actuate Therapeutics (ACTU) Total Non-Current Liabilities (2023 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Total Non-Current Liabilities of $404991.0 for Q4 2025, down 1.64% year-over-year from $411759.0 in Q4 2024, and little changed quarter-over-quarter from $404991.0 in Q3 2025.
Actuate Therapeutics (ACTU) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Total Non-Current Liabilities for 3 consecutive years, with $404991.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 1.64% year-over-year to $404991.0; the TTM figure through Dec 2025 stood at $404991.0 (down 1.64% YoY), while the FY2025 annual figure was $404991.0, down 1.64% from the prior year.
- Total Non-Current Liabilities was little changed at $404991.0 in Q4 2025 per ACTU's latest filing, from $404991.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.7 million in Q2 2024 and bottomed at $404991.0 in Q3 2025.
- Historically, Total Non-Current Liabilities has averaged $715775.1 across 3 years, with a median of $414290.5 in 2024.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 0.42% in 2025 and fell as far as 75.7% in 2025.
- Actuate Therapeutics' Total Non-Current Liabilities stood at $1.5 million in 2023, then slumped by 72.97% to $411759.0 in 2024, then dropped by 1.64% to $404991.0 in 2025.
- Business Quant data shows ACTU's Total Non-Current Liabilities at $404991.0 in Q4 2025, $404991.0 in Q3 2025, and $421884.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 9.32 Bn |
| 10 | Actuate Therapeutics | 29.84 Mn | 29.84 Mn | - | 404,991.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 404,991.00 |
| Sep 30, 2025 | 404,991.00 |
| Jun 30, 2025 | 421,884.00 |
| Mar 31, 2025 | 416,822.00 |
| Dec 31, 2024 | 411,759.00 |
| Sep 30, 2024 | 406,683.00 |
| Jun 30, 2024 | 1.74 Mn |
| Dec 31, 2023 | 1.52 Mn |